SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017. Key issues identified were that most patients did not recognize DKA, treating physicians often did not initially recognize DKA due to relative euglycemia, and effective treatment was delayed.